SynthesisMedicine2021

Anlotinib, a novel TKI, as a third-line or further-line treatment in patients with advanced non-small cell lung cancer in China: A systemic review and meta-analysis of its efficacy and safety.

Haiyong Ye et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.